Informações:
Falhas:
ID
26601
Descrição
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00845910
Link
https://clinicaltrials.gov/show/NCT00845910
Palavras-chave
Versões (1)
- 21/10/2017 21/10/2017 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
21 de outubro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00845910
Eligibility Breast Cancer NCT00845910
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00845910
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Gender | Age
Item
female patients, 18-65 years of age;
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Breast cancer recurrent Local | Secondary malignant neoplasm of female breast
Item
locally recurrent and metastatic breast cancer;
boolean
C0278493 (UMLS CUI [1,1])
C0205276 (UMLS CUI [1,2])
C0346993 (UMLS CUI [2])
C0205276 (UMLS CUI [1,2])
C0346993 (UMLS CUI [2])
Measurable Disease | Evaluable Disease
Item
measurable or evaluable disease;
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
C1516986 (UMLS CUI [2])
ECOG performance status
Item
ecog performance status of 0-2;
boolean
C1520224 (UMLS CUI [1])
Left ventricular ejection fraction | Sign or Symptom Absent Heart failure
Item
lvef >=50% without clinical symptoms or signs of heart failure.
boolean
C0428772 (UMLS CUI [1])
C3540840 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0018801 (UMLS CUI [2,3])
C3540840 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0018801 (UMLS CUI [2,3])
HER2/Neu Status Unknown | HER2/Neu Positive
Item
unknown her2 status, or known her2-positive status;
boolean
C2348910 (UMLS CUI [1])
C2348909 (UMLS CUI [2])
C2348909 (UMLS CUI [2])
Chemotherapy Recurrent disease Local | Chemotherapy Neoplasm Metastasis
Item
prior chemotherapy for locally recurrent or metastatic disease;
boolean
C0392920 (UMLS CUI [1,1])
C0277556 (UMLS CUI [1,2])
C0205276 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C0027627 (UMLS CUI [2,2])
C0277556 (UMLS CUI [1,2])
C0205276 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C0027627 (UMLS CUI [2,2])
Taxane Adjuvant therapy | Taxane Neoadjuvant Therapy
Item
prior adjuvant or neoadjuvant taxane therapy within 12 months prior to start of treatment;
boolean
C0215136 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
C0215136 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
C0677850 (UMLS CUI [1,2])
C0215136 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
CNS metastases Evidence of
Item
clinical or radiological evidence of cns metastases;
boolean
C0686377 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0332120 (UMLS CUI [1,2])
Cardiovascular Disease
Item
clinically significant cardiovascular disease.
boolean
C0007222 (UMLS CUI [1])